IL-ADVANCED-CLINICAL
9.3.2022 00:54:08 CET | Business Wire | Press release
Advanced Clinical, a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey, is pleased to announce that Dr. Andreas Amrein has joined the Executive Team as Senior Vice President of Asia-Pacific (APAC) and Japan as well as Managing Director for Europe and Canada.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220308006375/en/
Dr. Amrein will be instrumental to the organization’s continued expansion and strengthening of Advanced Clinical’s current operations into the APAC region, which include offices in Singapore, Australia and Japan. He’ll also oversee development and expansion opportunities for additional locations across Europe and Canada, complementing the company’s existing footprint inclusive of 10 office locations in Europe as well as an office in Toronto, Canada.
With over 20 years of international leadership experience, Dr. Amrein has led many teams and organizations across over 30 geographies, including Fortune 100 companies (Novartis, Abbott and Shire) and dynamic start-ups.
“From my specialization in rapid commercial expansions, launches, transformations, partnerships and more across Asia and around the globe, I look forward to leveraging my knowledge to help Advanced Clinical further establish quality operations internationally,” said Dr. Amrein.
“We are excited to have Andreas on our team as we continue to expand into the APAC region and Japan,” said Julie Ross, President of Advanced Clinical. “Andreas will be instrumental in accelerating business growth as we diversify our global clinical programs and elevate our clinical strategy for the clients and patients we serve. After our successful entry into the region in 2021 combined with additional APAC office openings planned for 2022, Andreas will undoubtedly help elevate our presence across the APAC, European and Canadian regions as a global leader in clinical research, FSP and strategic resourcing services.”
About Advanced Clinical
Advanced Clinical is a clinical development and strategic resourcing organization committed to providing a better clinical experience across the drug development journey. Our goal is to improve the lives of all those touched by clinical research – approaching each opportunity with foresight, character, resilience and innovation. Based on decades of experience, we help our clients achieve better outcomes by conducting candid conversations and anticipating potential issues through our customized solutions. Visit our website to learn more: www.advancedclinical.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220308006375/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe's Largest Halloween Festival Marks 40 Years in the Birthplace of Halloween27.10.2026 13:37:00 CET | Press release
As Derry Halloween celebrates 40 years, festivals across the island of Ireland bring more than 2,000 years of Halloween tradition to life Rooted in the ancient Celtic festival of Samhain, which marked the end of the harvest season and the beginning of winter more than 2,000 years ago, Halloween can trace its origins to Ireland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261020759137/en/ Derry Halloween, Co. Derry~Londonderry This year, the story comes full circle as Derry Halloween, Europe's oldest and largest Halloween festival, celebrates its 40th anniversary, leading a programme of events across the island that blend history, storytelling, music, food and spectacle. Derry Halloween began organically as a community celebration in 1985, when a Halloween fancy-dress party in a local pub was evacuated during a security alert at the height of the Troubles, sending revellers onto the streets and sparking a tradition that wo
Effort Inflation Puts Brand Loyalty at Risk, Netcracker/CSG Research Finds27.10.2026 13:30:00 CET | Press release
2027 State of the Customer Experience Report shows customers turn to third-party AI for help, while effective automation and human support strengthen loyalty Netcracker/CSG® today released the 2027 State of the Customer Experience Report, which finds that “Effort Inflation,” the growing time, steps, and mental effort customers must use to engage with brands, is damaging trust and loyalty. The findings show that customers will stay with brands that make touchpoints faster and easier, ensure continuity across channels, and preserve access to human support when needed. One consequence of Effort Inflation is the rise of a “shadow customer experience” layer, where customers turn to third-party AI assistants and personal agents to navigate brand interactions, pushing critical touchpoints out of the brand’s control. As more support journeys shift outside owned channels, brands risk losing visibility, context, and opportunities to build trust. This trend reinforces the need for connected, effo
AHS Properties to Launch USD 1.3 Billion AHS Twin Towers, a Grade A Commercial Office Building on Sheikh Zayed Road27.10.2026 13:17:00 CET | Press release
AHS Properties is set to launch AHS Twin Towers, its new commercial development on Sheikh Zayed Road, following the AED 1.1 billion acquisition of Shangri-La Dubai. The property will undergo a major transformation into a Grade A commercial destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027110920/en/ Abbas Sajwani, Founder and CEO of AHS Properties (Photo: AETOSWire) Positioned on one of Dubai’s most prominent commercial corridors, AHS Twin Towers will introduce a new architectural identity for the property. The project has been designed by Gensler, an internationally recognised architecture and design firm, with interiors by AHS Atelier, the company’s in-house design studio, bringing a bespoke approach to materiality, detailing and craftsmanship throughout the development. AHS Twin Towers will comprise ground floor plus 50. The development will offer flexible Grade A office environments supported by an integr
JERA Signs a Binding Heads of Agreement with AM Green for Long-Term Supply of Green Ammonia for Maritime Decarbonization27.10.2026 13:11:00 CET | Press release
JERA Co., Inc. (JERA) and AM Green Ammonia (India) Private Limited (AM Green) today jointly announced that it has entered into a Binding Heads of Agreement ("HoA") with AM Green regarding the long-term supply of green ammonia produced in India. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027189014/en/ JERA and AM Green have agreed upon supply of approximately 70,000 tonnes of green ammonia annually over five years, with potential extension of term for additional supply. The green ammonia is intended to be supplied through receiving, storage and distribution facilities being developed adjacent to JERA's Hekinan Thermal Power Station in Aichi Prefecture, Japan. Green ammonia would primarily be supplied to a business venture jointly to be established by Kawasaki Kisen Kaisha, Ltd. and Nippon Yusen Kabushiki Kaisha, which plans to utilize an ammonia bunkering vessel to supply fuel to ammonia-fueled car carriers. This marks
Pythia Labs Launches with AI-Designed Antibodies for Hard-to-Drug Targets27.10.2026 13:00:00 CET | Press release
Biotech startup demonstrates rapid AI design of full-length human antibodies that inhibit or activate GPCRs, with key properties required for therapeutic development Pythia Labs, a biotechnology company building frontier AI models for therapeutic discovery, today announced its launch alongside a preprint in bioRxiv introducing Pythia-1, the all-atom generative model at the core of its antibody design platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261027891477/en/ Pythia's AI technology platform can design antibodies against traditionally challenging targets such as multi-pass membrane proteins. Pythia’s technology is built to create antibodies against targets that have challenged conventional discovery, including multi-pass membrane proteins such as G protein-coupled receptors (GPCRs). Generating antibodies that activate these receptors has been a longstanding goal in antibody discovery. Pythia-1 reasons jointly ov
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom